| scholarly article | Q13442814 |
| P50 | author | Faustino Mollinedo | Q88826407 |
| P2093 | author name string | Consuelo Gajate | |
| Ximena Bonilla | |||
| El-Habib Dakir | |||
| P2860 | cites work | ASK1 is essential for endoplasmic reticulum stress-induced neuronal cell death triggered by expanded polyglutamine repeats | Q24298956 |
| Fis1 and Bap31 bridge the mitochondria-ER interface to establish a platform for apoptosis induction | Q24320479 | ||
| Caspase cleavage product of BAP31 induces mitochondrial fission through endoplasmic reticulum calcium signals, enhancing cytochrome c release to the cytosol | Q24675708 | ||
| Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer. | Q27853104 | ||
| Involvement of raft aggregates enriched in Fas/CD95 death-inducing signaling complex in the antileukemic action of edelfosine in Jurkat cells | Q28475228 | ||
| Intracellular triggering of Fas, independently of FasL, as a new mechanism of antitumor ether lipid-induced apoptosis | Q30647113 | ||
| Chemical and physiological characterization of fluo-4 Ca(2+)-indicator dyes | Q30855902 | ||
| Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: Surveillance Epidemiology and End Results data. | Q31157886 | ||
| Interval compressed vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide, etoposide in patients with advanced Ewing's and other Small Round Cell Sarcomas | Q33403469 | ||
| ET-18-OCH3 (edelfosine): a selective antitumour lipid targeting apoptosis through intracellular activation of Fas/CD95 death receptor | Q33983532 | ||
| Lipid raft-targeted therapy in multiple myeloma. | Q34112080 | ||
| Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. | Q34320295 | ||
| Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects | Q34806351 | ||
| Antitumor alkyl ether lipid edelfosine: tissue distribution and pharmacokinetic behavior in healthy and tumor-bearing immunosuppressed mice. | Q34935395 | ||
| Biological activities, mechanisms of action and biomedical prospect of the antitumor ether phospholipid ET-18-OCH(3) (edelfosine), a proapoptotic agent in tumor cells | Q34946588 | ||
| Metformin repositioning as antitumoral agent: selective antiproliferative effects in human glioblastoma stem cells, via inhibition of CLIC1-mediated ion current | Q34957274 | ||
| Cyclophosphamide and cancer: golden anniversary | Q35005506 | ||
| Involvement of lipid rafts in the localization and dysfunction effect of the antitumor ether phospholipid edelfosine in mitochondria | Q35064991 | ||
| Microtubules, microtubule-interfering agents and apoptosis. | Q35219575 | ||
| Metformin: multi-faceted protection against cancer | Q35764409 | ||
| Targeted therapy in Ewing sarcoma | Q36011879 | ||
| Survival and apoptotic signals in the action of microtubule-targeting antitumor drugs | Q36032960 | ||
| A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial | Q46984013 | ||
| The use of paediatric chemotherapy protocols at full dose is both a rational and feasible treatment strategy in adults with Ewing's family tumours | Q48566319 | ||
| Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma. | Q50921097 | ||
| Involvement of mitochondria and caspase-3 in ET-18-OCH(3)-induced apoptosis of human leukemic cells. | Q52538556 | ||
| Endoplasmic reticulum stress in the proapoptotic action of edelfosine in solid tumor cells. | Q53518926 | ||
| The Biology of Ewing sarcoma. | Q53575285 | ||
| Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in in vitro and in vivo xenograft models. | Q55070716 | ||
| Involvement of c-Jun NH2-terminal kinase activation and c-Jun in the induction of apoptosis by the ether phospholipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine | Q74454386 | ||
| Editorial: Antitumor alkylphospholipid analogs: a promising and growing family of synthetic cell membrane-targeting molecules for cancer treatment) | Q87440374 | ||
| Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts | Q36050677 | ||
| Stress induction of GRP78/BiP and its role in cancer. | Q36393494 | ||
| The biology of ewing sarcoma | Q36546372 | ||
| How to target apoptosis signaling pathways for the treatment of pediatric cancers | Q36610528 | ||
| Drug uptake, lipid rafts, and vesicle trafficking modulate resistance to an anticancer lysophosphatidylcholine analogue in yeast | Q36708592 | ||
| Ewing sarcoma: historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future | Q37182432 | ||
| Targeting the apoptosome for cancer therapy | Q37369655 | ||
| Ewing's sarcoma: standard and experimental treatment options | Q37522056 | ||
| Metformin sensitizes anticancer effect of dasatinib in head and neck squamous cell carcinoma cells through AMPK-dependent ER stress | Q37649672 | ||
| The molecular pathogenesis of Ewing's sarcoma | Q37705751 | ||
| Lipid rafts and clusters of apoptotic signaling molecule-enriched rafts in cancer therapy. | Q37750797 | ||
| Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects | Q38016107 | ||
| Cancer stem cells in pediatric sarcomas | Q38118769 | ||
| Current view on the mechanism of action of perifosine in cancer | Q38195878 | ||
| Lipid rafts, endoplasmic reticulum and mitochondria in the antitumor action of the alkylphospholipid analog edelfosine. | Q38195882 | ||
| Metformin, an old drug, brings a new era to cancer therapy | Q38393435 | ||
| Metformin inhibits growth and sensitizes osteosarcoma cell lines to cisplatin through cell cycle modulation | Q39061212 | ||
| Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines. | Q39149019 | ||
| Perifosine induces cell apoptosis in human osteosarcoma cells: new implication for osteosarcoma therapy? | Q39270813 | ||
| Antitumor alkyl-lysophospholipid analog edelfosine induces apoptosis in pancreatic cancer by targeting endoplasmic reticulum. | Q39447548 | ||
| miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy | Q39465507 | ||
| Caspase-4 directly activates caspase-9 in endoplasmic reticulum stress-induced apoptosis in SH-SY5Y cells. | Q39599805 | ||
| Novel anti-inflammatory action of edelfosine lacking toxicity with protective effect in experimental colitis. | Q39879484 | ||
| Identification of cancer stem cells in Ewing's sarcoma | Q39885066 | ||
| Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy | Q40009768 | ||
| Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells | Q40135808 | ||
| Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. | Q40227228 | ||
| Rapid and selective apoptosis in human leukemic cells induced by Aplidine through a Fas/CD95- and mitochondrial-mediated mechanism. | Q40657531 | ||
| Further characterization of human fetal osteoblastic hFOB 1.19 and hFOB/ER alpha cells: bone formation in vivo and karyotype analysis using multicolor fluorescent in situ hybridization | Q40706676 | ||
| miR-125b develops chemoresistance in Ewing sarcoma/primitive neuroectodermal tumor | Q41051759 | ||
| Development and characterization of a conditionally immortalized human fetal osteoblastic cell line | Q41376369 | ||
| Bcl-X(L) specifically activates Bak to induce swelling and restructuring of the endoplasmic reticulum | Q41889229 | ||
| Intracellular triggering of Fas aggregation and recruitment of apoptotic molecules into Fas-enriched rafts in selective tumor cell apoptosis | Q41933362 | ||
| Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. | Q42162649 | ||
| Selective induction of apoptosis in cancer cells by the ether lipid ET-18-OCH3 (Edelfosine): molecular structure requirements, cellular uptake, and protection by Bcl-2 and Bcl-X(L). | Q42802374 | ||
| Early and selective induction of apoptosis in human leukemic cells by the alkyl-lysophospholipid ET-18-OCH3. | Q42810244 | ||
| Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. | Q43023369 | ||
| In vitro and In vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts | Q43127276 | ||
| Induction of apoptosis in leukemic cells by the reversible microtubule-disrupting agent 2-methoxy-5-(2',3',4'-trimethoxyphenyl)-2,4,6-cycloheptatrien-1 -one: protection by Bcl-2 and Bcl-X(L) and cell cycle arrest. | Q43503487 | ||
| Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer | Q43786836 | ||
| The antitumor ether lipid ET-18-OCH(3) induces apoptosis through translocation and capping of Fas/CD95 into membrane rafts in human leukemic cells | Q43819664 | ||
| Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone | Q44320806 | ||
| P433 | issue | 16 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | endoplasmic reticulum | Q79927 |
| P304 | page(s) | 14596-14613 | |
| P577 | publication date | 2015-06-01 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Endoplasmic reticulum targeting in Ewing's sarcoma by the alkylphospholipid analog edelfosine | |
| P478 | volume | 6 |
| Q98945426 | Doxorubicin and Edelfosine Combo-Loaded Lipid-Polymer Hybrid Nanoparticles for Synergistic Anticancer Effect Against Drug-Resistant Osteosarcoma |
| Q58579097 | The anti-psychotic drug pimozide is a novel chemotherapeutic for breast cancer |
| Q49787815 | Upregulation of cell cycle genes in head and neck cancer patients may be antagonized by erufosine's down regulation of cell cycle processes in OSCC cells. |
Search more.